ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis
Joint Authors
Yadav, Dipesh Kumar
Bai, Xue li
Lou, Jianying
Que, Risheng
Gao, Shunliang
Wang, Ji
Hua, Yong Fei
Zhang, Yun
Xie, Qinfen
Edoo, Muhammad Ibrahim Alhadi
Chutturghoon, Vikram Kumar
Liang, Ting-Bo
Source
Gastroenterology Research and Practice
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-16, 16 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-06-11
Country of Publication
Egypt
No. of Pages
16
Main Subjects
Abstract EN
Aim.
The primary aim of this study is to compare the short- and long-term outcomes between ABO-incompatible (ABOi) adult living donor liver transplantation (ALDLT) with rituximab prophylaxis and ABO-compatible (ABOc) ALDLT.
Background.
The strategy of ABOi liver transplantation (LT) was originated initially to increase the donor pool and to enable liver transplantation in emergency conditions.
However, ABOi ALDLT remains a controversial approach in comparison to ABOc ALDLT.
Methods.
PubMed, Embase, and the Cochrane Library study search were accomplished to recognize studies comparing ABOi and ABOc ALDLT.
Meta-analyses were conducted based on the evaluation of heterogeneity using a fixed-effect model and a random-effect model to assess the short- and long-term outcomes following ABOi ALDLT with rituximab prophylaxis.
Results.
Nine studies comprising a total of 3,922 patients (ABOi=671 and ABOc=3,251) were identified.
There was no significant difference between ABOi and ABOc groups for 1-year, 3-year, and 5-year OS and graft survival, respectively.
Moreover, 1-year and 3-year OS and DFS were similar between both groups for HCC patients.
However, ABOi ALDLT had higher incidences of CMV infection, AMR, overall biliary complications, and biliary stricture than ABOc ALDLT and had other comparable postoperative complications.
Conclusion.
Our meta-analysis included studies comparing ABOi and ABOc ALDLT after the introduction of rituximab in a desensitization protocol for ABOi ALDLT.
The results of ABOi ALDLT were comparable with those of ABOc ALDLT.
However, biliary complications, CMV infection, and AMR remain a concern in the era of rituximab.
American Psychological Association (APA)
Yadav, Dipesh Kumar& Hua, Yong Fei& Bai, Xue li& Lou, Jianying& Que, Risheng& Gao, Shunliang…[et al.]. 2019. ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis. Gastroenterology Research and Practice،Vol. 2019, no. 2019, pp.1-16.
https://search.emarefa.net/detail/BIM-1155527
Modern Language Association (MLA)
Yadav, Dipesh Kumar…[et al.]. ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis. Gastroenterology Research and Practice No. 2019 (2019), pp.1-16.
https://search.emarefa.net/detail/BIM-1155527
American Medical Association (AMA)
Yadav, Dipesh Kumar& Hua, Yong Fei& Bai, Xue li& Lou, Jianying& Que, Risheng& Gao, Shunliang…[et al.]. ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis. Gastroenterology Research and Practice. 2019. Vol. 2019, no. 2019, pp.1-16.
https://search.emarefa.net/detail/BIM-1155527
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1155527